Option chain shows key data for PPlus Tr GSC-2 Tr Ctf Fltg Rate's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for PPlus Tr GSC-2 Tr Ctf Fltg Rate.

PPlus Tr GSC-2 Tr Ctf Fltg Rate (NYSE:PYT) Stock, Option Chain

PPlus Tr GSC-2 Tr Ctf Fltg Rate

March 27,2010: Inflation Protected Securities. Good Insurance For The Income Investor.

Pyng Medical Third Quarter Fiscal 2009 Financial Results

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 12, 2009) - Pyng Medical Corp. (the &#34;Company&#34;) (TSX VENTURE:PYT) announces, further to its press releases dated May 14, 2009, May 25, 2009 and July 9, 2009, that it has closed the first tranche of its non-brokered private placement (the &#34;Private Placement&#34;) of secured subordinated convertible notes (the &#34;Notes&#34;) and common share purchase warrants (the &#34;Warrants&#34;).

Pyng Medical Announces Closing of Private Placement

Playtech PLC

Pyth Network - United States dollar

Many investors are weary of the miserly interest rates at their local bank and through Uncle Sam. They want safety. They do not want to loan out money practically free. They would like inflation protection over and above what TIPS provide. 
The following select roster of securities will provide a stout yield with protection from inflation. All are rated Moody's Baa3 or higher. Most are trading at a discount from their $25.00 (or, rarely, $100.00) call price. Libor's are three month rates unless indicated differently. No caps for a maximum rate unless indicated.
This article is not to be considered a portfolio recommendation. The securities listed may be investigated for inclusion as a part of a diversified investment scheme. Most are thinly traded.
Aegeon Floating Rate(<a class="ticker" href="/stock/aeb#">AEB</a>) Libor+.875 with 4.00% floor. $20.22/share. CABCO Trust (<a class="ticker" href="/stock/gyb#">GYB</a>) Libor+.85 with 3.25% floor and 8.25% cap. $19.12/share. CABCO Trust (<a class="ticker" href="/stock/gyc#">GYC</a>) Libor+.65 with 3.25% floor and 8.00% cap. $20.62/share. Goldman Sachs Pref. A (GSPRA) Libor+.75 with a 3.75% floor. $22.15/share. Goldman Sachs Pref. C (GSPRC) Libor+.75 with a 4.00% floor. $23.98/share Goldman Sachs Pref. D (GSPRD) Libor+.67 with a 4.00% floor. $22.39/share HSBC Pref. D(HBAPRD) based upon 1-30 year T-bill basket with a 4.50% floor. 10.5% cap.$23.90/share. HSBC Pref. G (HBAPRG)Libor+.75 with a 4.00% floor.$23.39/share. HSBC Pref. F (HBAPRF) Libor+.75 with a 3.5% floor. $22.50/share Lehman Trust Cert. (<a class="ticker" href="/stock/jbk#">JBK</a>) Libor+.75 with a 3.50% floor and 7.5% cap. $19.70/share. MetLife Pref. A (METPRA) Libor+1.00 with a 4.00% floor. $23.79/share. Goldman Sachs Cap I Certificates (<a class="ticker" href="/stock/pyt#">PYT</a>)Libor+.85 with a 3.00% floor and 8.00% cap. $18.29/share. JP Morgan Floating Rate Certificates (<a class="ticker" href="/stock/pyv#">PYV</a>) 83% of CMT with a 3.00% floor and 9.25% cap. $25.40/share. Morgan Stanley Pref. Series A (MSPFA) Libor+.70 with a 4.00% floor. $21.80/share. Prudential Financial Inflation-Linked Notes (<a class="ticker" href="/stock/pfk#">PFK</a>) CPI+2.40%. $24.39/share. Santander Finance Series 6 Pref. (STDPFB) Libor+.52 with a 4.00% floor. $18.80/share. Southern California Edison Series A Pref.(SCEDN) Highest of Libor, 10-year CMT or 30-year CMT+1.45%.$99.75/share. Tennessee Valley Authority PARRS/A Power Bond (<a class="ticker" href="/stock/tve#">TVE</a>) 30-year CMT+.84%. $26.00/share. Tennessee Valley Authority PARRS/B Power Bond (<a class="ticker" href="/stock/tvc#">TVC</a>) 30-year CMT+.94%. $26.58/share. U.S. Bancorp Series B Pref. (USBPRH) Libor+.60 with a 3.5% floor.$21.86/share. UBS Pref. Trust IV (UBSPRD) 1-month Libor+.70. $16.89/share.
My favorites are PFK and SCEDN. The author has a position in PFK. 
<div class="blogger-post-footer"><img width='1' height='1' src='https://blogger.googleusercontent.com/tracker/33358029-110780097968505867?l=investingfromtheright.blogspot.com' alt='' /></div>

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 18, 2009) - Pyng Medical Corp. (TSX VENTURE:PYT) released its unaudited third quarter fiscal 2009 results for the period ending June 30, 2009.
An exclusive prime vendor agreement was signed with Tri-anim Health Services, Inc. (Sarnova LLC) to extend the company's products into the hospital market. Tri-anim Health Services will exclusively distribute the FAST1(R) Intraosseous Infusion System for IO procedures and the TPOD(R) Pelvic Stabilizer to various hospital facilities within the US.
Pyng Medical's June 2008 asset acquisition of BioCybernetics International products is beginning to pay dividends, both in revenue contribution and our strategic objective to diversify the customer base. The company's focus on building the EMS and Hospital customer base is evidenced by the Q2 to Q3 revenue growth in the MAT(R) Tourniquet of 96% and a 174% increase in the T-POD(R) Pelvic Stabilizer binding system. The company's CRIC(TM) Cricothyrotomy System, having received the European medical CE mark is expected to be shipped in September to Canada, Europe and Asia-Pacific distributors.
The Company's sales for the third quarter of fiscal 2009 were $1,288,743 and sales for year to date were $4,307,905; which was comparable to $4,380,943 for fiscal 2008 year to date. Our flagship product, the FAST1(R) Intraosseous Infusion System, is the largest selling Sternal IO System with over 197,000 units shipped to-date.
Cost of sales for the third quarter of fiscal 2009 was $388,451 providing a gross margin of $900,292 or 70%. Total operating expenses for the quarter decreased from $922,528 for the third quarter of fiscal 2008 to $879,603 for the third quarter fiscal 2009. On a percentage basis, operating expenses increased from 57% of sales for the quarter ended June 30, 2008 to 68% for the quarter ended June 30, 2009. The Company recorded a net loss before tax of $101,518 for the quarter ending June 30, 2009. This was attributed to the sales of the FAST1(R) Intraosseous Infusion System which were negatively impacted due to a decreased injury rate for military personnel and civilians.
Full financial results for third quarter fiscal 2009 are available on SEDAR at <a href="http://www.sedar.com" title="www.sedar.com">www.sedar.com</a>.
About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Creators of the FAST1(R) Intraosseous Infusion System, Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company's proprietary FAST1(R), the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the "2007 TSX Venture 50" Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006. In June 2008, the Company expanded its product portfolio four-fold by acquiring the trauma assets of California-based Bio Cybernetics International (BCI), including the market leading T-POD(R) Pelvic Stabilizer, MAT(R) Tourniquet and CRIC(TM) Cricothyrotomy System.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 12, 2009) - Pyng Medical Corp. (the "Company") (TSX VENTURE:PYT) announces, further to its press releases dated May 14, 2009, May 25, 2009 and July 9, 2009, that it has closed the first tranche of its non-brokered private placement (the "Private Placement") of secured subordinated convertible notes (the "Notes") and common share purchase warrants (the "Warrants"). Total gross proceeds of $547,725 were raised through the sale of $545,000 principal amount of Notes and proceeds of $2,725 for 2,725,000 Warrants.
For details of the Notes and Warrants, please refer to the Company's press releases dated May 14, 2009, May 25, 2009 and July 9, 2009.
All securities issued or issuable pursuant to the first tranche of the Private Placement are subject to a hold period expiring December 11, 2009. Proceeds of the Private Placement will be used by the Company for general working capital and continued development of its products.
The Private Placement is subject to the final approval of the TSX Venture Exchange.
About Pyng Medical Corp.
Pyng Medical Corp. commercializes award-winning trauma and resuscitation products for front-line critical care personnel. Creators of the FAST1(R) Intraosseous Infusion System, Pyng's expanded product portfolio includes a variety of innovative, lifesaving tools. With growing markets in North America, Europe and Asia, Pyng offers user-preferred medical devices for use by hospital staff, emergency medical services and military forces worldwide. Pyng has received the exclusive 2008 Medical Device Company of the Year Award from Life Sciences British Columbia for its sustained achievements in commercializing the Company's proprietary FAST1(R), the only medical device able to provide rapid sternal access for administering drugs and fluids to the heart in seconds. The Company was also selected in the "2007 TSX Venture 50" Top 10 companies in Life Sciences based on solid financial metrics for the year ending December 31, 2006.
Safe Harbour Statement; Forward-Looking Statements: This release may contain forward-looking statements based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Some of the forward-looking statements may be identified by words like "expects", "anticipates", "plans", "intends", "projects", "indicates", and similar expressions. These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions. Many factors, including those discussed more fully elsewhere in this release and in documents which may be filed with the British Columbia Securities Commission, the Alberta Securities Commission, the Ontario Securities Commission, the TSX Venture Exchange, as well as other USA Commissions, could cause results to differ materially from those stated. These factors include, but are not limited to changes in the laws, regulations, policies and economic conditions, including inflation, interest and foreign currency exchange rates, of countries in which the Company does business; competitive pressures; successful integration of structural changes, including restructuring plans, acquisitions, divestitures and alliances; cost of raw material, research and development of new products, including regulatory approval and market acceptance; and seasonality of sales in some products.

Comments

PPlus Tr GSC-2 Tr Ctf Fltg Rate

PPlus Tr GSC-2 Tr Ctf Fltg Rate (PYT) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga